Technology Overview

In 2019, Taiwan aligned with EU regulations banning animal testing in cosmetics. ITRI developed a 3D bioprinting technology for full-thickness human skin tissue, which enables cell culture and differentiation within just 6 days. By integrating bio-ink materials, skin cell differentiation protocols, and an automated 3D bioprinting system, the EPiTRI platform achieves pilot production of over 300 skin tissues per batch with a yield rate above 85%.

Technical Superiority

1. Temperature-controlled bioprinting ensures both cell viability and biomaterial stability throughout the printing process.

2. Capable of processing high-viscosity bio-inks (＜ 5,000 mPa·s), effectively overcoming the limitations of conventional inkjet printing.

3. A three-printhead configuration enables multi-material and composite tissue bioprinting with high precision.

4. The EPiTRI platform demonstrates well-defined epidermal layer formation and functional skin barrier characteristics.

5. Applicable for in vitro cosmetic irritation/corrosion testing,  compliant with OECD TG 439 and 431.

Application

1. Tissue engineering, regenerative medicine, drug development, biomedical research

2. In vitro cosmetic safety evaluation: skin irritation and corrosion testing

3. Screening and development of new active ingredients, formulations, and products

4. Melanin-containing epidermal models for skin whitening product development

5. Testing applications for new drug and medical device development

6. Evaluation of new chemicals and environmental toxicants

7. Assessment of percutaneous absorption of drugs/chemicals